Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

La Jolla Pharmaceutical stock price, quote, forecast and news

LJPC
US5034596040
A1XB6B

Price

6.22
Today +/-
+0
Today %
+0 %
P

La Jolla Pharmaceutical stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the La Jolla Pharmaceutical stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the La Jolla Pharmaceutical stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the La Jolla Pharmaceutical stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze La Jolla Pharmaceutical's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

La Jolla Pharmaceutical Stock Price History

DateLa Jolla Pharmaceutical Price
8/22/20226.22 undefined
8/19/20226.22 undefined

La Jolla Pharmaceutical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into La Jolla Pharmaceutical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by La Jolla Pharmaceutical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects La Jolla Pharmaceutical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of La Jolla Pharmaceutical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into La Jolla Pharmaceutical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing La Jolla Pharmaceutical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on La Jolla Pharmaceutical’s growth potential.

La Jolla Pharmaceutical Revenue, EBIT and net profit per share

DateLa Jolla Pharmaceutical RevenueLa Jolla Pharmaceutical EBITLa Jolla Pharmaceutical Net Income
2026e93.75 M undefined77.6 M undefined75.07 M undefined
2025e87.23 M undefined44.5 M undefined30.03 M undefined
2024e77.41 M undefined18.25 M undefined12.25 M undefined
2023e65.23 M undefined8.93 M undefined6 M undefined
2022e53.84 M undefined2.28 M undefined1.04 M undefined
202175.72 M undefined21.83 M undefined19.66 M undefined
202033.42 M undefined-35.84 M undefined-39.42 M undefined
201923.05 M undefined-109.8 M undefined-116.51 M undefined
201810.06 M undefined-194.05 M undefined-199.47 M undefined
20170 undefined-115.43 M undefined-114.8 M undefined
2016620,000 undefined-78.37 M undefined-78.19 M undefined
20151.06 M undefined-41.97 M undefined-41.91 M undefined
20140 undefined-21.34 M undefined-21.31 M undefined
20130 undefined-17.94 M undefined-18.74 M undefined
20120 undefined-10.74 M undefined-8.52 M undefined
20110 undefined-2.27 M undefined-11.67 M undefined
20100 undefined-3.93 M undefined-4.23 M undefined
20098.13 M undefined-8.64 M undefined-8.63 M undefined
20080 undefined-60.73 M undefined-62.85 M undefined
20070 undefined-55.69 M undefined-53.08 M undefined
20060 undefined-42.13 M undefined-39.45 M undefined
20050 undefined-28 M undefined-27.36 M undefined
20040 undefined-40.74 M undefined-40.54 M undefined
20030 undefined-39.29 M undefined-38.84 M undefined
20020 undefined-44.64 M undefined-43.32 M undefined

La Jolla Pharmaceutical Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022e2023e2024e2025e2026e
00034984000000000800000100102333755365778793
----33.33125.00-11.11-50.00-------------------130.0043.48127.27-29.3322.6418.4612.996.90
--------------------------80.0086.9675.7682.67-----
00000000000000000000000000820256200000
-5-8-10-9-10-7-9-9-15-27-44-39-40-28-42-55-60-8-3-2-10-17-21-41-78-115-194-109-352128184477
----300.00-250.00-77.78-112.50-225.00----------100.00------4,100.00---1,940.00-473.91-106.0628.003.7712.3123.3850.5782.80
-4-7-10-8-9-6-7-9-13-24-43-38-40-27-39-53-62-8-4-11-8-18-21-41-78-114-199-116-391915123075
-75.0042.86-20.0012.50-33.3316.6728.5744.4484.6279.17-11.635.26-32.5044.4435.9016.98-87.10-50.00175.00-27.27125.0016.6795.2490.2446.1574.56-41.71-66.38-148.72-94.74400.00140.00150.00150.00
00000000000000000000.010.21.5410.6715.6517.2321.2225.4227.1127.3334.1800000
-----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The La Jolla Pharmaceutical Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the La Jolla Pharmaceutical is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021
7.71423.724.22723.411.439.94752.732.123.172.942.939.419.44.36.953.48.648.6126.565.790.9172.687.821.246.67
00040000000000000000000001.435.88.61
00000000000000000000000000000
000000000000000000000000022.266.28
0.20.30.21.20.70.50.50.60.60.710.80.9110.80.60.10.1001.711.73.15.14.53.45.76
7.914.323.929.427.723.911.940.547.653.433.123.973.843.940.420.24.975.13.48.650.3127.567.494181.197.536.467.32
1.82.31.91.40.90.70.70.81.966.26.142.31.30.4000000.31.73.124.622.333.90.80.43
00000000000000000000000000000
00000000000000000000000000000
0.40.50.60.91.11.31.51.72.22.42.63.13.13.32.80.30000000000014.913.32
00000000000000000000000000020.120.12
0000000000000000000000100200900900900040
2.22.82.52.3222.22.54.18.48.89.27.15.64.10.7000000.31.83.325.523.234.835.833.92
10.117.126.431.729.725.914.14351.761.841.933.180.949.544.520.94.975.13.48.650.6129.370.7119.5204.3132.372.2101.23
0.40.10.10.20.20.20.20.30.40.40.50.10.30.30.40.6005.110.910.36.76.66.66.66.63.93.93.91
26.443.962.276.180.384.384.4124.9158.2206.9228.4258.9337.1342.5385.9418.5428.5428.6424.1439.7462.7528.4646.4661.1803.1950.3977.4984.8986.45
-19.9-30.2-38.8-48.4-54.7-62.6-71.8-85.6-110.2-153.6-192.4-232.9-260.3-299.8-352.8-415.7-424.3-428.1-439.6-447.4-465.3-486.6-528.5-606.7-721.5-921-1,037.3-1,076.8-1,057.09
00000001002000-100000000000000000000
00000000000000000000000000000
6.913.823.527.925.821.912.839.748.653.736.426.177.14333.53.44.20.5-10.43.27.748.5124.56188.235.9-56-88.1-66.74
0.80.70.31.51.31.30.20.50.71.80.31.50.92.12.24.60.1000.10.80.73.16.711.58.64.22.82.28
0.30.30.81.41.30.90.82.82.24.63.13.92.33.98.16.50.50.30.20.10.31.41.83.15.71620.49.610.18
00001.31.8000000000006.115.3000001.41.4002.85
0000000000000005.90000000000000
0.50.70.80.60.100.200.20.50.80.90.50.20.10.20000000000002.33
1.61.71.93.5441.23.33.16.94.26.33.76.210.417.20.66.415.50.21.12.14.99.818.62624.612.417.64
1.61.60.90.2000001.11.30.70.10.20.40.20000000000000
00000000000000000000000000000
00000000000000000000000012.8142.4163.7148150.33
1.61.60.90.2000001.11.30.70.10.20.40.20000000012.8142.4163.7148150.33
3.23.32.83.7441.23.33.185.573.86.410.817.40.66.415.50.21.12.14.99.831.4168.4188.3160.4167.97
10.117.126.331.629.825.9144351.761.741.933.180.949.444.320.84.86.95.13.48.850.6129.470.8119.6204.3132.372.3101.23
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of La Jolla Pharmaceutical provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand La Jolla Pharmaceutical's financial health and stability.

Assets

La Jolla Pharmaceutical's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that La Jolla Pharmaceutical must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of La Jolla Pharmaceutical after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into La Jolla Pharmaceutical's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021
-4-7-10-8-9-6-7-9-13-24-43-38-40-27-39-53-62-8-3-11-7-17-21-41-78-114-199-116-3919
000000000011221100000000014421
000000000000000000000000000000
0000-350-2203-32-2241-7000001460-6-17-5
00000000000000557009512714142142331611
000000000000000000000000000200
000000000000000000000000000000
-4-6-9-7-110-7-11-11-24-38-40-35-27-29-41-53-16-3-1-2-4-12-25-58-84-152-84-3728
000000000-1-5-2-20000000000-1-2-9-2000
02-2-1-14225-24-7-16165-46263241000000-1-2-9-20-300
12-2-1-13225-24-5-10187-4627424100000000000-300
000000000000000000000000000000
0030000000100-1005-6000000000000
10121890004033482129780382860001053104012011201-2
101617123304032502129770383406001053104011923601-2
00003330000000000060000000124000
000000000000000000000000000000
-2-438-1350-631-4-1-13-205-52-1-153977-602581-84-6725
-5.51-7.35-10.06-7.62-12.33-0.61-7.49-12.15-12.79-25.92-43.66-42.37-38.54-27.77-30.02-42.56-53.8-16.55-3.39-1.83-2.14-4.77-13.14-27-60.89-94.07-154.71-85.65-37.6428.24
000000000000000000000000000000

La Jolla Pharmaceutical stock margins

The La Jolla Pharmaceutical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of La Jolla Pharmaceutical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for La Jolla Pharmaceutical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the La Jolla Pharmaceutical's sales revenue. A higher gross margin percentage indicates that the La Jolla Pharmaceutical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the La Jolla Pharmaceutical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the La Jolla Pharmaceutical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the La Jolla Pharmaceutical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the La Jolla Pharmaceutical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the La Jolla Pharmaceutical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

La Jolla Pharmaceutical Margin History

La Jolla Pharmaceutical Gross marginLa Jolla Pharmaceutical Profit marginLa Jolla Pharmaceutical EBIT marginLa Jolla Pharmaceutical Profit margin
2026e82.19 %82.78 %80.08 %
2025e82.19 %51.01 %34.42 %
2024e82.19 %23.57 %15.83 %
2023e82.19 %13.69 %9.19 %
2022e82.19 %4.23 %1.94 %
202182.19 %28.83 %25.96 %
202076.6 %-107.24 %-117.95 %
201989.63 %-476.36 %-505.47 %
201883.6 %-1,928.93 %-1,982.8 %
201782.19 %0 %0 %
201682.19 %-12,640.32 %-12,611.29 %
201582.19 %-3,959.43 %-3,953.77 %
201482.19 %0 %0 %
201382.19 %0 %0 %
201282.19 %0 %0 %
201182.19 %0 %0 %
201082.19 %0 %0 %
200982.19 %-106.27 %-106.15 %
200882.19 %0 %0 %
200782.19 %0 %0 %
200682.19 %0 %0 %
200582.19 %0 %0 %
200482.19 %0 %0 %
200382.19 %0 %0 %
200282.19 %0 %0 %

La Jolla Pharmaceutical Stock Sales Revenue, EBIT, Earnings per Share

The La Jolla Pharmaceutical earnings per share therefore indicates how much revenue La Jolla Pharmaceutical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue La Jolla Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates La Jolla Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of La Jolla Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating La Jolla Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

La Jolla Pharmaceutical Revenue, EBIT and net profit per share

DateLa Jolla Pharmaceutical Sales per ShareLa Jolla Pharmaceutical EBIT per shareLa Jolla Pharmaceutical Earnings per Share
2026e3.67 undefined0 undefined2.94 undefined
2025e3.41 undefined0 undefined1.18 undefined
2024e3.03 undefined0 undefined0.48 undefined
2023e2.55 undefined0 undefined0.23 undefined
2022e2.11 undefined0 undefined0.04 undefined
20212.22 undefined0.64 undefined0.58 undefined
20201.22 undefined-1.31 undefined-1.44 undefined
20190.85 undefined-4.05 undefined-4.3 undefined
20180.4 undefined-7.63 undefined-7.85 undefined
20170 undefined-5.44 undefined-5.41 undefined
20160.04 undefined-4.55 undefined-4.54 undefined
20150.07 undefined-2.68 undefined-2.68 undefined
20140 undefined-2 undefined-2 undefined
20130 undefined-11.65 undefined-12.17 undefined
20120 undefined-53.7 undefined-42.6 undefined
20110 undefined-227 undefined-1,167 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined
20030 undefined0 undefined0 undefined
20020 undefined0 undefined0 undefined

La Jolla Pharmaceutical business model

La Jolla Pharmaceutical Co is a biopharmaceutical company specializing in the development and marketing of medicines for the treatment of rare and severe diseases. It was founded in 1989 in San Diego, California, by physician and scientist Ivor Royston. The company's business model is focused on researching, developing, and marketing drugs for patients with rare or severe diseases. The company prioritizes the needs and requirements of patients and aims to tailor each medication to maximize effectiveness. La Jolla's main focus is on researching medications for severe and rare diseases such as sepsis, acute kidney failure, and lung inflammation. These medications are intended to help patients who have limited or no treatment options. The company's portfolio includes various drugs, with antibodies being an important component for the treatment of inflammation and autoimmune diseases. Notably, Giapreza is one of the company's well-known medications approved by the FDA in December 2017, designed to treat adult patients with severe or most severe septic shock by increasing blood pressure. LJPC-401 is another significant medication developed by La Jolla Pharmaceutical Co, intended for the treatment of lupus nephritis, an autoimmune-related kidney inflammation that affects about 50% of systemic lupus erythematosus (SLE) patients. The company is also working on the development of a medication for migraine treatment, aiming to reduce the severity and frequency of migraine attacks. Overall, La Jolla Pharmaceutical Co has made significant progress in expanding its research activities and is committed to developing innovative medications to improve the lives of patients with rare and severe diseases. The company's focus on patient needs has proven to be a strategic advantage, positioning it competitively for the future. La Jolla Pharmaceutical is one of the most popular companies on Eulerpool.com.

La Jolla Pharmaceutical SWOT Analysis

Strengths

La Jolla Pharmaceutical Co has a strong product portfolio comprising of innovative and effective medications. This robust portfolio gives them a competitive edge in the pharmaceutical industry and helps drive revenue and market share growth.

The company invests significantly in research and development, resulting in the continuous development of new drugs and treatments. This strengthens their position in the market and ensures a pipeline of potential blockbuster products.

La Jolla Pharmaceutical Co has established strategic partnerships with renowned academic institutions, healthcare organizations, and industry leaders. These collaborations provide access to valuable resources, expertise, and potential synergies, enhancing the company's overall market position.

Weaknesses

The company faces challenges in expanding its market reach, as it primarily operates in specific therapeutic areas. This narrow focus limits their customer base and potential market share growth.

La Jolla Pharmaceutical Co heavily relies on a few key products for a significant portion of its revenue. Any disruptions or failures related to these products could have a substantial negative impact on the company's financial performance.

Opportunities

With the increasing globalization of healthcare, there is a growing opportunity for La Jolla Pharmaceutical Co to expand its reach to emerging markets. These markets offer untapped potential and a chance to diversify revenue streams.

The rapid advancements in healthcare technology create opportunities for La Jolla Pharmaceutical Co to develop and market innovative and more efficient drugs. Embracing cutting-edge technologies can enhance the company's competitive position and attract new customers.

Threats

The pharmaceutical industry is highly competitive, with numerous established players and new entrants. La Jolla Pharmaceutical Co faces the constant threat of competitors launching similar or superior drugs, potentially eroding their market share.

Strict regulations and compliance requirements in the pharmaceutical sector can pose challenges for La Jolla Pharmaceutical Co. Delays in obtaining necessary approvals or changes in regulations may impact the company's ability to bring products to market in a timely and cost-effective manner.

The expiration of patents on key products can expose La Jolla Pharmaceutical Co to increased competition from generic drug manufacturers. This may lead to a decline in sales and profitability unless the company can successfully develop new patented drugs.

La Jolla Pharmaceutical Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

La Jolla Pharmaceutical historical P/E ratio, EBIT, and P/S ratio.

La Jolla Pharmaceutical shares outstanding

The number of shares was La Jolla Pharmaceutical in 2023 — This indicates how many shares 34.179 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue La Jolla Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates La Jolla Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of La Jolla Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating La Jolla Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

La Jolla Pharmaceutical Stock splits

In La Jolla Pharmaceutical's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for La Jolla Pharmaceutical.

La Jolla Pharmaceutical list of shareholders

%
Name
Stocks
Change
Date
9.11 % RTW Investments L.P.2,327,403-5003/31/2022
4.95 % Healthinvest Partners AB1,265,000558,0006/30/2022
37.60 % Tang Capital Management, LLC9,607,934-240,0007/10/2022
3.23 % The Vanguard Group, Inc.825,481-3,9623/31/2022
2.70 % Medical Strategy GmbH689,585-58,5673/31/2022
2.35 % D. E. Shaw & Co., L.P.600,07011,2683/31/2022
1.87 % Acadian Asset Management LLC477,68842,3013/31/2022
1.61 % BlackRock Institutional Trust Company, N.A.410,200-1,9193/31/2022
1.38 % Tang (Kevin C)352,000112,0007/10/2022
1.02 % Norges Bank Investment Management (NBIM)259,676259,6763/31/2021
1
2
3
4
5
...
10

La Jolla Pharmaceutical Executives and Management Board

Mr. Larry Edwards50
La Jolla Pharmaceutical President, Chief Executive Officer, Director (since 2020)
Compensation 2.62 M
Mr. Michael Hearne58
La Jolla Pharmaceutical Chief Financial Officer
Compensation 658,014
Mr. Craig Johnson59
La Jolla Pharmaceutical Independent Director
Compensation 292,865
Ms. Laura Douglass56
La Jolla Pharmaceutical Independent Director
Compensation 162,597
Mr. David Ramsay56
La Jolla Pharmaceutical Independent Director
Compensation 162,597
1
2

Most common questions regarding La Jolla Pharmaceutical

What values and corporate philosophy does La Jolla Pharmaceutical represent?

La Jolla Pharmaceutical Co represents values of innovation, dedication, and excellence in the pharmaceutical industry. With a strong corporate philosophy centered around advancing healthcare, the company strives to develop and commercialize life-changing therapies for patients in need. La Jolla Pharmaceutical Co is committed to conducting rigorous research, fostering collaborations, and utilizing cutting-edge technology to deliver novel treatment options. By putting patients first and ensuring the highest quality standards, La Jolla Pharmaceutical Co remains at the forefront of delivering transformative healthcare solutions.

In which countries and regions is La Jolla Pharmaceutical primarily present?

La Jolla Pharmaceutical Co is primarily present in the United States.

What significant milestones has the company La Jolla Pharmaceutical achieved?

La Jolla Pharmaceutical Co has achieved several significant milestones. Firstly, the company successfully developed and launched its flagship product, Giapreza, a medication used for the treatment of low blood pressure. This achievement marked a significant breakthrough in the field of critical care medicine. Additionally, La Jolla Pharmaceutical Co obtained the approval from the U.S. Food and Drug Administration (FDA) for Giapreza, further validating its effectiveness and safety. The company has also focused on advancing its research pipeline, conducting clinical trials, and securing partnerships to drive innovation and growth in the pharmaceutical industry. Overall, La Jolla Pharmaceutical Co has demonstrated remarkable progress in developing life-saving treatments and garnering regulatory approvals.

What is the history and background of the company La Jolla Pharmaceutical?

La Jolla Pharmaceutical Co is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for life-threatening diseases. Founded in 1989, La Jolla Pharmaceutical Co has a rich history in advancing medical research and delivering breakthrough treatments to patients. It has a strong portfolio of products targeting conditions like sepsis and specific organ dysfunction. With a commitment to scientific excellence and patient welfare, La Jolla Pharmaceutical Co continues to push the boundaries of healthcare innovation. As a reputable player in the pharmaceutical industry, La Jolla Pharmaceutical Co's dedication to enhancing patient outcomes remains steadfast.

Who are the main competitors of La Jolla Pharmaceutical in the market?

The main competitors of La Jolla Pharmaceutical Co in the market are companies such as Amgen Inc., Gilead Sciences Inc., and Biogen Inc.

In which industries is La Jolla Pharmaceutical primarily active?

La Jolla Pharmaceutical Co is primarily active in the biotechnology industry.

What is the business model of La Jolla Pharmaceutical?

The business model of La Jolla Pharmaceutical Co. revolves around developing and commercializing innovative therapies to improve outcomes in patients suffering from life-threatening diseases. La Jolla Pharmaceutical focuses on the discovery, development, and commercialization of proprietary therapeutics for patients with significant unmet medical needs. The company strives to bring groundbreaking treatments to the market that address critical medical challenges. La Jolla Pharmaceutical Co.'s commitment to research and development, along with strategic partnerships, enables the company to deliver effective solutions and make a meaningful impact on patients' lives.

What is the P/E ratio of La Jolla Pharmaceutical 2024?

The La Jolla Pharmaceutical P/E ratio is 17.35.

What is the P/S ratio of La Jolla Pharmaceutical 2024?

The La Jolla Pharmaceutical P/S ratio is 2.75.

What is the AlleAktien quality score of La Jolla Pharmaceutical?

The AlleAktien quality score for La Jolla Pharmaceutical is 3/10.

What is the revenue of La Jolla Pharmaceutical 2024?

The expected La Jolla Pharmaceutical revenue is 77.41 M USD.

How high is the profit of La Jolla Pharmaceutical 2024?

The expected La Jolla Pharmaceutical profit is 12.25 M USD.

What is the business model of La Jolla Pharmaceutical

La Jolla Pharmaceutical Co is a research-oriented biopharmaceutical company that focuses on the discovery, development, and marketing of innovative therapies for serious diseases. The company is headquartered in San Diego, California. The business model of La Jolla Pharmaceutical Co specializes in the development and marketing of biologic drugs. The company is involved in the following areas: - Development of drugs for serious diseases La Jolla Pharmaceutical Co has focused on the development of drugs for serious diseases such as sepsis, shock, and severe organ dysfunction. The company uses its own proprietary technology platform to develop novel therapeutic antibodies. - Distribution of drugs in the USA La Jolla Pharmaceutical Co is a pharmaceutical company that focuses on the distribution of drugs in the USA. The company has an experienced sales team that is responsible for the distribution of products in the market. The products are distributed directly to hospitals, clinics, and pharmacies as well as through wholesalers. - Research and development of new products La Jolla Pharmaceutical Co invests a significant portion of its revenue from product sales into research and development of new products. The company has a dedicated team of researchers and scientists specializing in the development of new and innovative therapies for serious diseases. The products of La Jolla Pharmaceutical Co include the following: - Giapreza (Angiotensin II injection solution) Giapreza is the main product of La Jolla Pharmaceutical Co. It is an injection solution used for the treatment of patients with severe or life-threatening hypovolemic shock. This condition is characterized by a drop in blood pressure and inadequate blood supply to the heart. - Xerava (Eravacycline injection) Xerava is an antibiotic used for the treatment of severe Gram-negative bacterial infections. - Vabriolix (Croxinjektion) Vabriolix is an antibiotic used for the treatment of nosocomial and complicated urinary tract infections. In summary, La Jolla Pharmaceutical Co is a research-oriented biopharmaceutical company that focuses on the discovery, development, and marketing of innovative therapies for serious diseases. The company has focused on the development of drugs for serious diseases such as sepsis, shock, and severe organ dysfunction. La Jolla Pharmaceutical Co has an experienced sales team responsible for the distribution of products in the market, as well as a dedicated team of researchers and scientists specialized in the development of new and innovative therapies. The products of La Jolla Pharmaceutical Co include antibiotics and injection solutions for the treatment of serious and life-threatening diseases.

What is the La Jolla Pharmaceutical dividend?

La Jolla Pharmaceutical pays a dividend of 0 USD distributed over payouts per year.

How often does La Jolla Pharmaceutical pay dividends?

The dividend cannot currently be calculated for La Jolla Pharmaceutical or the company does not pay out a dividend.

What is the La Jolla Pharmaceutical ISIN?

The ISIN of La Jolla Pharmaceutical is US5034596040.

What is the La Jolla Pharmaceutical WKN?

The WKN of La Jolla Pharmaceutical is A1XB6B.

What is the La Jolla Pharmaceutical ticker?

The ticker of La Jolla Pharmaceutical is LJPC.

How much dividend does La Jolla Pharmaceutical pay?

Over the past 12 months, La Jolla Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, La Jolla Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of La Jolla Pharmaceutical?

The current dividend yield of La Jolla Pharmaceutical is .

When does La Jolla Pharmaceutical pay dividends?

La Jolla Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of La Jolla Pharmaceutical?

La Jolla Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of La Jolla Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is La Jolla Pharmaceutical located?

La Jolla Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von La Jolla Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of La Jolla Pharmaceutical from 8/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/11/2024.

When did La Jolla Pharmaceutical pay the last dividend?

The last dividend was paid out on 8/11/2024.

What was the dividend of La Jolla Pharmaceutical in the year 2023?

In the year 2023, La Jolla Pharmaceutical distributed 0 USD as dividends.

In which currency does La Jolla Pharmaceutical pay out the dividend?

The dividends of La Jolla Pharmaceutical are distributed in USD.

All fundamentals about La Jolla Pharmaceutical

Our stock analysis for La Jolla Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of La Jolla Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.